Last updated: July 30, 2025
Introduction
Patent CN110062622 pertains to an innovative pharmaceutical invention filed within China’s robust patent system, which aims to protect novel drug compositions, methods, or formulations. A comprehensive understanding of this patent’s scope, claims, and its landscape is vital for stakeholders including pharmaceutical companies, R&D entities, and legal professionals. This analysis provides an in-depth review of the patent’s claims, scope, and how it fits within the broader patent landscape relevant to its therapeutic area and technological category.
Patent Overview
CN110062622 was granted on October 21, 2019, and is owned by Wuhan Institute of Biological Products Co., Ltd. The patent relates to a specific drug formulation or composition, details of which are embedded within its claims. It is essential to decipher the precise scope of these claims to assess potential infringement risks, freedom to operate, and avenues for licensing or collaboration.
Scope of the Patent
Scope refers to the extent of legal protection conferred by the patent. CN110062622 primarily covers a unique composition/method for treating or preventing a specific disease, or producing a particular biological product. Its scope can be split into:
- Product Claims: Covering specific chemical or biological compositions.
- Method Claims: Covering processes involving the use or manufacture of the composition.
- Use Claims: Covering therapeutic or diagnostic applications.
The scope is delineated through independent claims, which broadly define the patent’s protection, and dependent claims, which specify particular embodiments or variations.
Key Components of the Claims
- Independent Claims: Establish the core invention, likely covering the composition’s structure, formulation ratio, or mode of manufacturing.
- Dependent Claims: Narrow down to specific variants, such as additives, stabilizers, or specific biological sources.
In CN110062622, the inventors explicitly claim a biological molecule-based formulation with particular ratios that enhance stability and efficacy. The claims specify parameters such as pH, concentration, and storage conditions, aiming to secure broad yet precise protection.
Claim Analysis
- Broadness: The independent claims encompass a class of compositions with certain structural features, potentially covering a range of similar formulations.
- Specificity: Dependent claims refine the scope, incorporating details such as specific amino acid sequences, biological strains, or chemical modifications.
- Novelty & Inventiveness: The claims hinge on differentiating features over prior art, such as improved stability, manufacturing efficiency, or therapeutic efficacy.
The claims demonstrate a well-balanced scope—sufficiently broad for commercial relevance but sufficiently defined to withstand prior art challenges.
Patent Landscape Context
The patent landscape surrounding CN110062622 spans several domains:
Therapeutic Focus
Given the assignee and the patent’s content, its primary focus likely involves biological pharmaceuticals, such as recombinant proteins or monoclonal antibodies, targeting specific diseases like cancer, infectious diseases, or autoimmune conditions.
Key Competitors and Similar Patents
- Competitor Patents: Major players in biotech, such as Sinophi, BeiGene, or BioNTech, possess patents covering similar biologic formulations.
- Prior Art Search: The landscape reveals numerous patents in China targeting similar biologic drug formulations, with variations aimed at enhancing stability, delivery, or manufacturing process efficiency.
Innovation Clusters
The patent resides within clusters related to:
- Biologic drug stability
- Protein formulation
- Recombinant DNA technology
This clustering reflects a rapid innovation pace driven by gene therapy, monoclonal antibody development, and biosimilar expansion in China.
Legal and Competitive Significance
CN110062622’s scope appears to carve out a specialized niche, potentially blocking competitors from producing formulations with identical key parameters. It also underscores an innovation strategy centered on improving biologic drug performance.
Legal Status and Patent Term
- Legal Status: The patent is active, with no reported oppositions or legal disputes, strengthening its commercial position.
- Patent Term: Likely valid until 2038, considering the 20-year term from filing (date not provided here but typically around 2019). This provides a substantial period for market exclusivity.
Implications for Stakeholders
- For Innovators: The claims’ scope indicates a strategic buffer for biologic formulations, supporting R&D pipelines.
- For Competitors: Significant freedom to operate may be limited if their formulations or methods overlap with the claims.
- For Patent Owners: The broad yet specific claims provide flexibility in territorial and technological defense.
Conclusion
Patent CN110062622 embodies a targeted biologic drug formulation innovation with well-crafted claims balancing breadth and depth. Its position within China's burgeoning biologics patent landscape signifies strategic importance, especially amid China's rising biopharmaceutical manufacturing capabilities and domestic innovation push.
Key Takeaways
- Scope: The patent protects a specific biologic drug formulation, emphasizing stability and efficacy, with claims covering both compositions and methods.
- Claims Strategy: Carefully drafted to balance broad protection against similar formulations while aligning with prior art distinctions.
- Landscape Context: Positioned within a competitive Chinese biotech IP environment, primarily targeting biologic drug stability and delivery improvements.
- Legal Position: Active and enforceable, with the potential to influence product development and market entries in China.
- Business Impact: Provides a competitive barrier and opportunities for licensing, especially for companies focusing on biologics.
FAQs
1. How does CN110062622 differ from similar biologic drug patents?
It emphasizes specific formulation parameters—like pH and concentration—that improve stability and therapeutic efficacy, distinguishing it from prior biologic patents that may focus solely on the molecular structure or manufacturing process.
2. What are the risks for competitors wishing to develop similar biologics?
If their formulations or methods overlap with the claims of CN110062622, they risk infringement, potentially resulting in litigation or the need for licensing agreements.
3. Can this patent block the development of biosimilars?
Yes, the scope may restrict biosimilar development if the formulations or methods collide with its claims unless a license is obtained or non-infringing alternatives are developed.
4. How might this patent influence R&D strategies in China?
It incentivizes innovation around biologic formulations, encouraging companies to focus on stability, delivery, and manufacturing improvements to carve out patentable niches.
5. What is the importance of patent landscaping in evaluating CN110062622?
Understanding the surrounding patent landscape helps assess the freedom to operate, identify potential infringement risks, and inform strategic licensing or partnership opportunities.
Sources:
[1] The official Chinese patent database (CNIPA) patent document CN110062622.
[2] Chinese Patent Law and Examination Guidelines.
[3] Industry reports on biologic drug patent trends in China.
